Barclays
ABUS icon

Barclays’s Arbutus Biopharma ABUS Stock Holding History

Barclays’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-75,000
Closed -$188K – 5039
2023
Q4 		$188K Buy
+75,000
New +$147K ﹤0.01% 4445
2018
Q3 		– Sell
-75,000
Closed -$548K – 7080
2018
Q2 		$548K Hold
75,000
– – ﹤0.01% 3869
2018
Q1 		$375K Buy
+75,000
New +$397K ﹤0.01% 4243

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Barclays's ABUS Position: Q1 2026 in Review

Barclays increased its Arbutus Biopharma (ABUS) stake by 1,110% in Q1 2026, buying an estimated $17.3M and bringing the position to 4,316,095 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1118.

Barclays first reported a position in ABUS in Q2 2013 and has held it in 40 quarters since. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Barclays held 4,316,095 shares of Arbutus Biopharma worth $19.4M as of Q1 2026.
  • Barclays bought 3,959,411 Arbutus Biopharma shares in Q1 2026, an estimated $17.3M.
  • Arbutus Biopharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1118 holding.
  • Barclays first reported a position in Arbutus Biopharma in Q2 2013 and has held it in 40 quarters since.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.